CDKN1B and pancreatic neoplasm: INBC057643 was developed as a BRD inhibitor, and it reduced cell proliferation and increased expression of p27, indicative of cell cycle arrest, in several murine and human pancreatic cancer lines (Figure 1A,B), as has been reported for other BRD4 inhibitors [24].